Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Moodys
Medtronic
McKesson
Johnson and Johnson

Last Updated: January 20, 2020

DrugPatentWatch Database Preview

OLAPARIB - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic drug sources for olaparib and what is the scope of patent protection?

Olaparib is the generic ingredient in one branded drug marketed by Astrazeneca Pharms and is included in two NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Olaparib has two hundred and seventy-eight patent family members in forty-nine countries.

There are three drug master file entries for olaparib. One supplier is listed for this compound.

Summary for OLAPARIB
International Patents:278
US Patents:8
Tradenames:1
Applicants:1
NDAs:2
Drug Master File Entries: 3
Suppliers / Packagers: 1
Bulk Api Vendors: 117
Clinical Trials: 230
Patent Applications: 380
DailyMed Link:OLAPARIB at DailyMed
Recent Clinical Trials for OLAPARIB

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Merck Sharp & Dohme Corp.Phase 2/Phase 3
Centre Georges Francois LeclercPhase 2
Yale UniversityPhase 2

See all OLAPARIB clinical trials

Pharmacology for OLAPARIB
Synonyms for OLAPARIB
(2H)-Phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-
09L
1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1
1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine
1(2H)-Phthalazinone, 4-[[3-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-
1021843-02-6
4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2H)-one
4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one
4-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one
4-(3-{[4-(Cyclopropylcarbonyl)piperazin-1-Yl]carbonyl}-4-Fluorobenzyl)phthalazin-1(2h)-One
4-[(3-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluoro-phenyl]methyl]-2H-phthalazin-1-one
4-[[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
4-[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorobenzyl]phthalazin-1(2H)-one
4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-1,2-dihydrophthalazin-1-one
4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-2H-phthalazin-1-one
4CA-0938
763113-22-0
894104-70-2
937799-91-2
A9666
AB0009952
AB1009702
ABP000423
AC-7939
ACN-032229
Acylpiperazine analogue, 47
AJ-101717
AKOS005145764
AN-493
AN-5279
ANW-43329
AOB1085
API0024518
AX8162101
AZ2281
AZD 2281
AZD 2281|||KU 0059436|||KU 59436
AZD-2281
AZD-2281 (Olaparib)
AZD2281
AZD2281,Olaparib, KU-0059436
AZD2281(olaparib)
AZD2281(olaparib)/AZD-2281/KU0059436
BB 0260909
BC245405
BCP01872
BCP9000363
BCPP000360
BDBM27566
BR-40514
BRD-K02113016-001-08-9
BRD-K02113016-001-09-7
cc-16
CHEBI:83766
CHEMBL521686
CS-0075
CTK8B3857
D09730
DB09074
EN002690
EX-7210
EX-A002
FDLYAMZZIXQODN-UHFFFAOYSA-N
FT-0083489
FT-0651458
GP0126
GTPL7519
HMS3654G13
HY-10162
I06-2362
J-503540
KS-00000HXY
KU-0059436
KU-59436
KU0059436
KU59436
Lynparza
Lynparza (TN)
MFCD13185161
MFCD13185161 (95%)
MLS006010185
MolPort-009-679-395
NCGC00238451-01
NCGC00238451-02
NCGC00238451-09
NSC-747856
NSC747856
Olaparib - AZD2281
Olaparib (AZD2281, Ku-0059436)
Olaparib (AZD2281, KU0059436)
Olaparib (AZD2281)
Olaparib (JAN/USAN/INN)
Olaparib [USAN:INN]
OLAPARIB cpd
Olaparib; KU 0059436
Olaparibum
PubChem19148
QC-2660
RL04905
S-3781
S-7836
s1060
SB14617
SC-65060
SCHEMBL426568
SMR004701291
SS-4573
SW218142-2
SY040527
UNII-WOH1JD9AR8
WOH1JD9AR8
Z-3275
ZINC40430143

US Patents and Regulatory Information for OLAPARIB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-001 Aug 17, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-001 Aug 17, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-001 Aug 17, 2017 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Astrazeneca Pharms LYNPARZA olaparib CAPSULE;ORAL 206162-001 Dec 19, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for OLAPARIB

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1633724 S1500012 Hungary   Start Trial PRODUCT NAME: OLAPARIB
1633724 C 2015 011 Romania   Start Trial PRODUCT NAME: OLAPARIB; NATIONAL AUTHORISATION NUMBER: EU/1/14/959/001; DATE OF NATIONAL AUTHORISATION: 20141216; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/959/001; DATE OF FIRST AUTHORISATION IN EEA: 20141216
1633724 1590019-4 Sweden   Start Trial PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REG. NO/DATE: EU/1/14/959 20141218
1633724 C20150012 00136 Estonia   Start Trial PRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014
1633724 2015/016 Ireland   Start Trial PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
1633724 C01633724/01 Switzerland   Start Trial PRODUCT NAME: OLAPARIB; REGISTRATION NO/DATE: SWISSMEDIC 65160 14.01.2016
1633724 13/2015 Austria   Start Trial PRODUCT NAME: OLAPARIB UND SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959 20141216
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Mallinckrodt
Merck
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.